Affimed N.V. (AFMD) Financial Analysis & Valuation | Quarter Chart
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clin... more
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing canc... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $2.98M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | DE | CEO | Shawn Leland |
| IPO Date | 2014-09-12 | CAGR | 19.44% |
| Employees | 76 | Website | www.affimed.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
AFMD chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $54.06M | P/E | -0.05 | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/CF | — | P/FCF | — |
| Sales | $1.02M | Sales 1Y | -95.39% | Sales 3Y | -97.8% | Sales 5Y | -97.82% |
| EPS | $-3.61 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | 0.65% | EPS QoQ | -6.93% | Sales QoQ Avg | -35.35% | EPS QoQ Avg | -12.63% |
| Gross Margin | 100% | Operating Margin | -1288.95% | Profit Margin | -1280.22% | ROCE | -149.7% |
| ROA | -109% | ROE | -101% | Altman Z Score | -25.64 | Piotroski Score | 1 |
| Current Ratio | 3.25 | Quick Ratio | 3.23 | Cash Ratio | 1.49 | Op. CF Ratio | -0.66 |
| Debt/Equity | 0.33 | Debt/Assets | 0.32 | Lt Debt/Equity | 0.35 | Lt Debt/Cap. | 0.1 |
| Intrst Cov. | -60.12 | Inventory Turnover | — | Asset Turnover | 0.09 | Receivables Turnover | 1.55 |
| Enterprise Value | $54.06M | P/E Ratio | -0.05 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $-3.61 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -95.39% | Gross Margin | 100% |
| Operating Margin | -1288.95% | Profit Margin | -1280.22% |
| ROE | -101% | ROA | -109% |
| ROCE | -149.7% | Current Ratio | 3.25 |
| Quick Ratio | 3.23 | Cash Ratio | 1.49 |
| Debt/Equity | 0.33 | Interest Coverage | -60.12 |
| Altman Z Score | -25.64 | Piotroski Score | 1 |
Affimed N.V. (AFMD) valuation & financials
Affimed N.V. (AFMD) has a market capitalization of $2.98M and trades at a price-to-earnings ratio of -0.1. It operates in the Healthcare sector (Biotechnology).
Affimed N.V.'s revenue grew -95.4% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)